Business
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023. Late Breaking Clinical Trial Title: REDWOOD-HCM-Cohort 4: Aficamten in Non-Obstructive HCMPresenter: Ahmad Masri, M.D. M.S., Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science UniversityDate: May 20, 2023Topic: TreatmentSession Title: Late-Breaking Clinical Trials: Chronic HF and CardiomyopathiesSession Type: Late Breaking ScienceSession Time: 4:00-5:00 PM CESTPresentation Time: 4:30 PM CESTLocation: Room 1 Moderated Poster Presentations Title: Risk of Safety Events Considered Potential Barriers to Utilization of Guideline-Directed Medical Therapy Among Patients with Worsening Heart failure and Ejection Fraction 30% or LowerPresenter: Stephen Greene, M.D., Division of Cardiology, Duke University Medical Center & Duke Clinical Research Institute Date: May 20, 2023Topic: PharmacotherapySession Title: Chronic Heart Failure - Pharmacotherapy 1Session Type: Moderated ePostersSession Time: 9:00-9:45 AM CESTLocation: Moderated ePosters 3 Title: Risk of Acute Heart Failure Events in Patients with Recent Worsening Heart Failure and Left Ventricular Ejection Fraction of 30% or Lower Presenter: Nihar R. Desai, M.D., MPH, Associate Professor of Medicine, Vice Chief, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation Date: May 21, 2023Topic: Epidemiology, Prognosis, OutcomeSession Title: Chronic Heart Failure - Epidemiology, Prognosis, Outcome 5Session Type: Moderated ePostersSession Time: 12:00-12:45 PM CESTLocation: Moderated ePosters 2 About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically enginee...